Vera Therapeutics (VERA) Change in Account Payables (2020 - 2026)

Vera Therapeutics (VERA) has 7 years of Change in Account Payables data on file, last reported at -$8.0 million in Q1 2026.

• Quarterly Change in Account Payables fell 598.81% year-over-year to -$8.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.3 million (up 7.25% YoY) and the FY2025 annual result came in at $13.9 million, up 502.84% from the prior year.
• Change in Account Payables declined to -$8.0 million in Q1 2026, from $3.6 million in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $8.0 million in Q2 2023 to a low of -$8.0 million in Q1 2026.
• A 5-year average of $719058.8 and a median of -$62000.0 in 2024 frame the typical range for Change in Account Payables.
• Annual changes were most pronounced in 2023 — Change in Account Payables plunged 1261.11% — and 2025, when it soared 7830.65%.
• Tracing VERA's Change in Account Payables over 5 years: stood at $5.0 million in 2022, then tumbled by 123.74% to -$1.2 million in 2023, then soared by 359.14% to $3.1 million in 2024, then gained by 18.35% to $3.6 million in 2025, then tumbled by 319.75% to -$8.0 million in 2026.
• The last three Change in Account Payables figures came in at -$8.0 million (Q1 2026), $3.6 million (Q4 2025), and $4.8 million (Q3 2025), per Business Quant data.